Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 242KB)
Why become a member?
 

Improvement in Fibromyalgia pain scale quantified

Tuesday 15 March 2011

Stethoscope

From HealthDay News (via Doctors Lounge):

 

Improvement in Fibromyalgia Pain Scale Quantified

Last Updated: March 08, 2011.

A two-point improvement on the Brief Pain Inventory represents the minimum clinically important difference for patients with fibromyalgia pain, corresponding to a 30 to 35 percent improvement from baseline, according to a study published online Feb. 10 in Arthritis Care & Research.

TUESDAY, March 8 (HealthDay News) -- A two-point improvement on the Brief Pain Inventory (BPI) represents the minimum clinically important difference (MCID) for patients with fibromyalgia pain, corresponding to a 30 to 35 percent improvement from baseline, according to a study published online Feb. 10 in Arthritis Care & Research.

Philip J. Mease, M.D., of the University of Washington School of Medicine in Seattle, and colleagues used data from four studies evaluating duloxetine as a treatment for fibromyalgia. They estimated the MCID for the BPI average pain item score and the BPI severity score by anchoring them against the Patient Global Impression of Improvement scale.

The researchers determined that an approximately two-point improvement on both the BPI average pain item and severity scores represented the MCID. These MCIDs corresponded to a 30 to 35 percent improvement in baseline pain in both scores.

"These findings may be beneficial for use in designing clinical trials in which the BPI is used to evaluate improvements in pain severity," the authors write.

The study received financial support from Eli Lilly and Company and Boehringer Ingelheim GmbH.

Abstract
Full Text (subscription or payment may be required)

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus

Previous Previous Page